Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 2/20 | 0.34 |
| ▸ | PPARD | Q03181 | 2/20 | 0.34 |
| ▸ | PPARA | Q07869 | 2/20 | 0.34 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14045210 | 0.86 | MAOB (0.37) | MAOBCYP1A1CYP1B1MAOANPC1 | |
| SCHEMBL13654072 | 0.85 | MAOB (0.41) | MAOBCYP1A1CYP1B1MAOANPC1 | |
| SCHEMBL13654100 | 0.80 | L3MBTL1 (0.46) | MAOBMAOANPC1RAB9AMAPT | |
| SCHEMBL13654097 | 0.72 | KMT2A (0.40) | MAOBNPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL13237239 | 0.70 | CYP1A2 (0.55) | MAOBCYP1A1CYP1B1NPC1RAB9A | |
| SCHEMBL13531014 | 0.69 | KMT2A (0.51) | MAOBMAOANPC1RAB9AMAPT | |
| SCHEMBL22804948 | 0.69 | NR4A2 (0.59) | MAOBNPC1RAB9ASMN1; SMN2PPARG | |
| SCHEMBL22804950 | 0.69 | NR4A2 (0.59) | MAOBNPC1RAB9ASMN1; SMN2PPARG | |
| SCHEMBL22804739 | 0.69 | MAOB (0.58) | MAOBNPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL22804742 | 0.69 | MAOB (0.58) | MAOBNPC1RAB9AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247488-A1 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | CANNIZZARO CARINA | 2009-10-01 | — | — | US | disclosed |
| US-20090247488-A1 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | CANNIZZARO CARINA | 2009-10-01 | — | — | US | disclosed |
| US-7432261-B2 | Anti-inflammatory phosphonate compounds | GILEAD SCIENCES, INC. (US) | 2008-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247488-A1 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | PHOSPHO1, TNF, PTGES | MAOB 4618/4885CYP1A1 4086/4885CYP1B1 3945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.